Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study

Sefid, Fatemeh; Payandeh, Zahra; Azamirad, Ghasem; Baradaran, Behzad; Nabi‐Afjadi, Mohsen; Islami, Mohammad Reza; Darvish, Maryam; Kalantar, Seyed Mehdi; Kahroba, Houman; Ardakani, Mahnam Alaei

doi:10.1007/s40203-021-00076-z

Cited by 7 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the expression of programmed death-1 / programmed death-ligand 1 (PD-1/PD-L1) and the genes with crucial functions in immune evasion are regulated by HDACs [ 121 , 122 ]. It has been demonstrated that HDACs can reversibly deacetylate the lysine residues in local histones; as a result, they could decline the expression of tumor suppressor genes in the case of melanoma [ 123 ].…”

Section: Role Of Epigenetic In Melanoma Development and Pathogenesismentioning

confidence: 99%

Current understanding of epigenetics role in melanoma treatment and resistance

et al. 2022

Self Cite

View full text Add to dashboard Cite

Melanoma is the most aggressive form of skin cancer resulting from genetic mutations in melanocytes. Several factors have been considered to be involved in melanoma progression, including genetic alteration, processes of damaged DNA repair, and changes in mechanisms of cell growth and proliferation. Epigenetics is the other factor with a crucial role in melanoma development. Epigenetic changes have become novel targets for treating patients suffering from melanoma. These changes can alter the expression of microRNAs and their interaction with target genes, which involves cell growth, differentiation, or even death. Given these circumstances, we conducted the present review to discuss the melanoma risk factors and represent the current knowledge about the factors related to its etiopathogenesis. Moreover, various epigenetic pathways, which are involved in melanoma progression, treatment, and chemo-resistance, as well as employed epigenetic factors as a solution to the problems, will be discussed in detail.

show abstract

Section: Role Of Epigenetic In Melanoma Development and Pathogenesismentioning

confidence: 99%

Current understanding of epigenetics role in melanoma treatment and resistance

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…9C and D). It is generally known that granzyme B and perforin synergize to mediate target cell apoptosis in NK-mediated killing (15,31). The present study detected the expression levels of granzyme B and perforin in culture medium from SHFM1-silenced or -overexpressed ESCC cells that co-cultured with NK-92 cells.…”

Section: Shfm1 Promotes Migration and Invasion Of Escc Cellsmentioning

confidence: 76%

SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance

Wang

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

Excessive proliferation, metastasis and immune escape are considered to be hallmarks of cancer contributing to tumor progression. Split hand and foot malformation 1 (SHFM1) is highly expressed in various cancers and has been reported to increase malignant behaviors. However, the biological functions of SHFM1 in esophageal squamous cell carcinomas (ESCC) progression remain to be elucidated. An integrated bioinformatics analysis was performed to identify candidate genes in ESCC progression based on GSE microarrays. SHFM1 was found to be profoundly upregulated in ESCC tissues compared with normal tissues and SHFM1 expression was positively associated with poor prognosis. The biological effects of SHFM1 on cell growth, metastasis and immune escape were investigated following depletion or overexpression of SHFM1 in vitro. A xenograft mouse model was established to investigate the effect of SHFM1 on ESCC progression in vivo. SHFM1 overexpression promoted ESCC cell proliferation and migration in vitro as well as tumorigenesis in vivo, while SHFM1 knockdown restored those phenotype changes. Additionally, the present study demonstrated that the effects of SHFM1 on malignant behaviors of ESCC cells were achieved by activating the NF-κB signaling accompanied by increased P65 phosphorylation and nuclear translocation. Furthermore, SHFM1 was also found to regulate the sensitivity of cancer cells to natural killer (NK) cells. Specifically, inhibition of SHFM1 enhanced cell-mediated cell apoptosis and increased NK toxicity, which might involve the downregulation of c-Myc and programmed death-ligand 1, key targets in cancer immunotherapy. In conclusion, these findings suggested that SHFM1 probably promoted ESCC progression by activating the NF-κB pathway and enhancing the resistance of ESCC cells to NK cell cytotoxicity, indicating that SHFM1 may be a promising target for ESCC treatment.

show abstract

“…In a different study, the collagen-structured anti-macrophage receptor was discovered to induce TAMs polarization into pro-inflammatory phenotypes, leading to anti-tumor immunological responses in B16 melanomas [ 36 ]. Furthermore, Gordon et al showed that suppression of PD-1/PD-L1 in vivo promoted macrophage phagocytosis, decreased tumor progression, and improved macrophage survival [ 16 , 144 ]. Lymphocyte-Activation Gene 3 (LAG-3, CD223) is another important immune checkpoint molecule that participates in T-cell exhaustion similar to Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed cell death protein 1 (PD-1) [ 145 ].…”

Section: Tumor-associated Macrophages In Melanomamentioning

confidence: 99%

Macrophage’s role in solid tumors: two edges of a sword

Jahandideh,

Yarizadeh,

Noei-Khesht Masjedi

et al. 2023

Cancer Cell Int

Self Cite

View full text Add to dashboard Cite

The tumor microenvironment is overwhelmingly dictated by macrophages, intimately affiliated with tumors, exercising pivotal roles in multiple processes, including angiogenesis, extracellular matrix reconfiguration, cellular proliferation, metastasis, and immunosuppression. They further exhibit resilience to chemotherapy and immunotherapy via meticulous checkpoint blockades. When appropriately stimulated, macrophages can morph into a potent bidirectional component of the immune system, engulfing malignant cells and annihilating them with cytotoxic substances, thus rendering them intriguing candidates for therapeutic targets. As myelomonocytic cells relentlessly amass within tumor tissues, macrophages rise as prime contenders for cell therapy upon the development of chimeric antigen receptor effector cells. Given the significant incidence of macrophage infiltration correlated with an unfavorable prognosis and heightened resistance to chemotherapy in solid tumors, we delve into the intricate role of macrophages in cancer propagation and their promising potential in confronting four formidable cancer variants—namely, melanoma, colon, glioma, and breast cancers.

show abstract

Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study

Cited by 7 publications

References 33 publications

Current understanding of epigenetics role in melanoma treatment and resistance

Current understanding of epigenetics role in melanoma treatment and resistance

SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance

Macrophage’s role in solid tumors: two edges of a sword

Contact Info

Product

Resources

About